Funding Freeze In Forecast For Next FDA Commissioner
This article was originally published in The Rose Sheet
Executive Summary
Commissioner Margaret Hamburg receives a warm farewell at a March 5 appropriations hearing, but the House subcommittee chair says fiscal 2016 funding likely will be flat. Hamburg’s pitch – that globalization has required a massive shift in agency thinking and reach – failed to move subcommittee members.
You may also be interested in...
FDA Personnel Growth Could Have Plateaued For Drugs Program
Only a handful of new FTEs are requested in President Obama’s FY 2016 budget request for human drugs activities, suggesting that GDUFA and other related programs may have reached their critical mass of employees for now.
FDA Chief Scientist Ostroff Named Acting Head With Hamburg On Way Out
Margaret Hamburg’s background in public health, as opposed to academic medicine, was off-putting to some in pharma initially, but she’ll leave the agency in March with high drug approval numbers and praise from industry groups. Chief Scientist Stephen Ostroff has been named acting head, and some speculate that Robert Califf, newly appointed deputy commissioner for medical products and tobacco, is in line to succeed Hamburg on a permanent basis.
Fourth Time’s A Charm? President’s FY 2016 Budget Includes Cosmetic Fees
Continuing what has become a familiar refrain, the Obama administration’s fiscal 2016 budget request for FDA includes cosmetics user fees, marking the fourth consecutive year that such a system has been proposed. Legislation would need to be introduced – and passed – in order to establish cosmetics user fees.